Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Aspirin Sensitivity Clear all
Active, not recruiting Phase 2 Interventional

Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease

NCT05575037
View directory record Official record
Conditions
Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions
Dupilumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 8:09 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Asprin Dosing Estimator in Healthy Adults

NCT04040465
View directory record Official record
Conditions
Aspirin Sensitivity
Interventions
Aspirin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Jul 22, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

NCT03326063
View directory record Official record
Conditions
Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jul 22, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

NCT01597375
View directory record Official record
Conditions
Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
Interventions
Placebo Oral Tablet, Prasugrel Oral Tablet
Drug
Lead sponsor
Elliot Israel, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jul 22, 2026, 8:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Carriers in the PAPI Study

NCT03188705
View directory record Official record
Conditions
Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 22, 2026, 8:09 AM EDT
Completed No phase listed Observational

Role of Inflammatory Mediators in AERD

NCT02824523
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
aspirin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Jul 22, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

NCT02216357
View directory record Official record
Conditions
Aspirin Exacerbated Respiratory Disease (AERD)
Interventions
Ifetroban, Oral Capsule, Placebo, Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Overland Park, Kansas • West Nyack, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jul 22, 2026, 8:09 AM EDT
Completed Phase 2 Interventional

Mechanisms of Dupilumab in AERD

NCT05031455
View directory record Official record
Conditions
Aspirin-exacerbated Respiratory Disease
Interventions
Aspirin Challenge
Drug
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 22, 2026, 8:09 AM EDT
Not listed Not applicable Interventional

Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

NCT00286416
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
omalizumab (Xolair)
Drug
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2006 · Synced Jul 22, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

NCT03028350
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
Ifetroban Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Lancaster, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jul 22, 2026, 8:09 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)

NCT04261582
View directory record Official record
Conditions
Aspirin Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma, Nasal Polyps
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 22, 2026, 8:09 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Mechanisms of Alcohol Sensitivity in AERD

NCT03441438
View directory record Official record
Conditions
Aspirin-Sensitive Asthma With Nasal Polyps, Samter's Syndrome
Interventions
Water, Red wine, Polyphenolic Compounds
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jul 22, 2026, 8:09 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction

NCT01047722
View directory record Official record
Conditions
Healthy
Interventions
Aspirin ingestion followed by doing a Bleeding Volume Test, Gatorade Placebo followed by Bleeding Volume Test.
Drug · Procedure
Lead sponsor
Klein, Jeffrey A., M.D.
Individual
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Newport Beach, California • San Juan Capistrano, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Jul 22, 2026, 8:09 AM EDT
Terminated No phase listed Observational Results available

Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease

NCT01320072
View directory record Official record
Conditions
Asthma, Aspirin-induced
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jul 22, 2026, 8:09 AM EDT
Completed Phase 4 Interventional Results available

Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

NCT00555971
View directory record Official record
Conditions
Aspirin Sensitivity
Interventions
Omalizumab, placebo
Drug
Lead sponsor
David Lang
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jul 22, 2026, 8:09 AM EDT